Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : Lung cancer patients in England to receive Amgen drug that targets a gene mutation

09/09/2021 | 07:01pm EDT

LONDON, Sept 10 (Reuters) - Lung cancer patients in England will become the first in Europe to receive a drug made by U.S. biotech Amgen Inc that targets a specific gene mutation, the country's health service said on Friday.

NHS England said it was fast-tracking lung cancer drug sotorasib after it was shown in clinical trials to stop lung cancer progression for seven months.

The drug, taken as a tablet, will be used on patients with the KRAS G12C mutation that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer.

The early-access deal will see 600 patients a year receive sotorasib in England through the state-run National Health Service (NHS).

"This revolutionary treatment has taken decades of research to reach the clinic, and now that it is here this new targeted drug will be available for eligible people with lung cancer as quickly as possible thanks to this agreement," said Peter Johnson, NHS clinical director for cancer.

Charles Swanton, chief clinician at charity Cancer Research UK, said the drug was "one of the most exciting breakthroughs in lung cancer treatment in 20 years, targeting a cancer gene that was previously untargetable."

The use of sotorasib in Britain follows its accelerated approval in May in the United States for lung cancer patients with the KRAS G12C mutation whose disease has worsened after treatment with chemotherapy or other medicines. It is sold in the United States under the brand name Lumakras.

Britain's medicine regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has authorised the drug under a partnership with U.S. and Australian counterparts designed to speed up approval for promising cancer treatments, called Orbis.

(Reporting by Alistair Smout Editing by Bill Berkrot)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. 0.51% 207.84 Delayed Quote.-10.06%
ORBIS AG 0.00% 7.75 Delayed Quote.21.09%
All news about AMGEN INC.
04:45aAnalysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
01:00aDeals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/13LUYE PHARMA : Chinese Regulators Accept Luye Pharma's Marketing Authorization for Osteopor..
MT
10/12AMGEN : Morgan Stanley Adjusts Amgen PT $235 from $251, Keeps Equalweight Rating
MT
10/11AMGEN : Working Together to Improve Public Health Outcomes
PU
10/08ADRs Close Higher; Oil Majors Trade Actively
DJ
10/08AMGEN : Discover What Fosters Innovation and Drives Change Through Amgen's Innovation2 Ser..
PU
10/08ASTRAZENECA : Gets US FDA's Orphan Drug Designation for Eosinophilic Esophagitis Drug
MT
10/08ASTRAZENECA : Tezepelumab Gets FDA Orphan Designation for Eosinophilic Esophagitis
DJ
10/07AMGEN : Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK..
PR
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 011 M - -
Net income 2021 5 797 M - -
Net Debt 2021 22 276 M - -
P/E ratio 2021 20,6x
Yield 2021 3,34%
Capitalization 117 B 117 B -
EV / Sales 2021 5,37x
EV / Sales 2022 5,04x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 207,84 $
Average target price 243,14 $
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-10.06%117 421
JOHNSON & JOHNSON1.73%421 487
ROCHE HOLDING AG15.58%336 383
PFIZER, INC.12.52%233 631
NOVO NORDISK A/S51.58%230 493
ELI LILLY AND COMPANY40.19%214 579